Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

While Roche’s Gazyva has been on the market for a dozen years and has won four approvals from the FDA, it is making a late ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...